Review
Immunology
Qian Li, Jingjing Han, Yonglin Yang, Yu Chen
Summary: Hepatocellular carcinoma (HCC) has a high prevalence and mortality rate worldwide. In recent years, immunotherapy using immune checkpoint inhibitors, particularly targeting the PD-1/PD-L1 axis, has brought fundamental changes to the treatment of advanced HCC. However, challenges remain and combination therapy may be a better option to improve the low remission rate.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Zihan Zhao, Siyang Liu, Rui Sun, Wenjie Zhu, Yulin Zhang, Tianyao Liu, Tianhang Li, Ning Jiang, Hongqian Guo, Rong Yang
Summary: Bladder cancer is a highly malignant tumor with limited improvement in prognosis and survival rates. Immune checkpoint inhibitors have revolutionized the treatment of bladder cancer, but their clinical application is limited by low response rates. This study investigated the combination of oxaliplatin and anti-PD-1 inhibitor in bladder cancer mouse models and found that this combination therapy was more efficient than medication alone.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Liting Zhong, Dehua Wu, Weiwei Peng, Hailong Sheng, Yazhi Xiao, Xuebing Zhang, Yuli Wang
Summary: The combination of PD-1/PD-L1 inhibitors with palliative radiotherapy and anti-angiogenic therapy appears to be safe and effective in treating hepatocellular carcinoma, with a significant impact on patient survival. Further studies are needed to explore the clinical benefits of this triple therapy approach.
FRONTIERS IN ONCOLOGY
(2021)
Review
Pathology
Marzieh Nikoo, Zahraa F. Hassan, Mahsa Mardasi, Elmira Rostamnezhad, Fatemeh Roozbahani, Sahel Rahimi, Javad Mohammadi
Summary: Hepatocellular carcinoma (HCC) is a deadly cancer with delayed symptom onset in most patients, leading to advanced stage diagnosis. PD-1 blockade therapy has shown promise in treating advanced HCC by activating exhausted tumor-infiltrating lymphocytes and improving T-cell function. However, not all HCC patients respond to this therapy and its clinical utility is limited by diverse immune-related adverse events (irAEs). Combinatory strategies, including combinations with other therapeutic methods, are being explored to improve outcomes, but may also result in increased side effects.
PATHOLOGY RESEARCH AND PRACTICE
(2023)
Article
Immunology
Hui Zeng, Qi Xu, Jinyu Wang, Xiaoqing Xu, Jun Luo, Lei Zhang, Cong Luo, Jieer Ying, Jingjing Li
Summary: This study found that the efficacy and safety of immune checkpoint inhibition (ICI) plus bevacizumab (BEV) and ICI plus receptor tyrosine kinase inhibitor (TKI) were similar as first-line treatments for unresectable hepatocellular carcinoma (uHCC).
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Haider S. Mahdi, Mary Woodall-Jappe, Preeti Singh, Myron S. Czuczman
Summary: This study evaluated the efficacy of adding E7777 to anti-PD-1 antibody therapy. Results showed that combination therapy with E7777 and anti-PD-1 led to increased anti-tumor activity and improved overall survival compared to monotherapy. Additionally, the combination therapy was able to counterbalance Treg cell infiltration induced by anti-PD-1 treatment.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Zhijie Wang, Yichuan Wang, Peng Gao, Jin Ding
Summary: The application of immune checkpoint inhibitors (ICIs) has greatly improved the treatment of hepatocellular carcinoma (HCC) and has resulted in prolonged survival for responsive patients. However, only a subset of HCC patients benefit from ICIs, and resistance can develop in initially responsive patients. Various factors contribute to ICI resistance, including the tumor microenvironment (TME), antigen expression and presentation, tumor heterogeneity, and gut microbiota. Investigating the mechanisms of ICI resistance is crucial to enhance the clinical benefit. Combination therapies have shown promise in preventing and reversing ICI resistance, and ongoing studies are exploring new combination therapies to overcome resistance.
Article
Oncology
Daniele V. F. Tauriello
Summary: The tumor microenvironment plays a crucial role in cancer progression and immune response. This study focuses on targeting cancer-associated fibroblasts to improve immunotherapeutic efficacy and treatment responses to checkpoint inhibitors in gastric tumors. The potential of multitarget tyrosine kinase inhibitors in treating gastrointestinal cancer is also explored.
Review
Medicine, General & Internal
Anne Dyhl-Polk, Marta Kramer Mikkelsen, Morten Ladekarl, Dorte Lisbet Nielsen
Summary: This comprehensive review discusses the development of immune checkpoint inhibitors in hepatocellular carcinoma (HCC), highlighting the potential for durable tumor remission and manageable safety profiles. While monotherapy with CPIs did not meet prespecified endpoints in phase III trials, combining CPIs with other agents may offer new treatment options for patients with HCC. Research on predictive biomarkers is essential for further development of CPIs in HCC.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Immunology
Yanan Wang, Boshizhang Peng, Chun Ning, Shuya He, Huayu Yang, Yilei Mao, Lejia Sun
Summary: This study identified mitophagy heterogeneity in hepatocellular carcinoma (HCC) and its association with immune status and prognosis. Two mitophagy-related subtypes with distinct prognoses, clinical characteristics, immune states, and biological function patterns were identified. The subtype with higher expression of mitophagy-related genes had worse survival outcomes, suppressed immune function, higher immune-checkpoint gene expression, and better response to immunotherapy. A risk model consisting of nine mitophagy-related genes was constructed and its performance was validated in two cohorts.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Masahiro Morita, Naoshi Nishida, Kazuko Sakai, Tomoko Aoki, Hirokazu Chishina, Masahiro Takita, Hiroshi Ida, Satoru Hagiwara, Yasunori Minami, Kazuomi Ueshima, Kazuto Nishio, Yukari Kobayashi, Kazuhiro Kakimi, Masatoshi Kudo
Summary: This study identified prognostic factors for anti-PD-1 antibody treatment in advanced HCC based on molecular and immunological features. Factors associated with better response included low alpha-fetoprotein levels, negative beta-catenin/GS staining, high CPS of PD-L1, and increased CD8(+) cell infiltration. Negative staining of beta-catenin/GS, CPS of PD-L1 >= 1, and high CD8(+) TILs were significantly associated with longer survival. These findings suggest that the combined score of Wnt/beta-catenin activation, CPS of PD-L1, and CD8(+) TILs can predict the response to ICI in HCC cases.
Article
Oncology
Sophia Z. Shalhout, Kevin S. Emerick, Howard L. Kaufman, Ann W. Silk, Manisha Thakuria, David M. Miller
Summary: Merkel cell carcinoma is a rare but highly aggressive skin cancer associated with UV exposure and viral infection. Immune checkpoint inhibitors have shown some clinical benefit in the treatment of advanced MCC, but resistance to these drugs remains a challenge. There is a lack of studies evaluating second-line systemic therapy for patients with resistance to anti-PD-(L)1 therapy.
JOURNAL OF IMMUNOTHERAPY
(2022)
Review
Biochemistry & Molecular Biology
Kai Hou, Xiaohui Xu, Xin Ge, Jiacen Jiang, Fan Ouyang
Summary: Immune checkpoints play a role in promoting tumor growth and inhibiting immune-mediated cancer cell apoptosis. Targeting immune checkpoints has been successful in treating various cancers, including hepatocellular carcinoma (HCC). However, some patients do not respond to this therapy due to acquired resistance and recurrence. Understanding the specific mechanisms of immune checkpoints in HCC development is crucial for improving the efficacy of anti-PD-1 and anti-CTLA-4 therapy.
Article
Nanoscience & Nanotechnology
Parisa Badiee, Michelle F. Maritz, Nicole Dmochowska, Edward Cheah, Benjamin Thierry
Summary: This study investigates the biodistribution of intratumorally administered aPD-1 nanoformulation and finds that it has lower off-target organ distribution and higher accumulation in tumors and tumor draining lymph nodes compared to free antibodies. In vitro studies also show that aPD-1 nanoformulation effectively inhibits PD-1 expression on T-cells and enhances their cytotoxicity against head and neck cancer cells. Further research is needed to assess the potential of intratumoral administration of aPD-1 nanoformulation in reducing toxicity and improving the tumor efficacy of immune checkpoint inhibitors.
ACS APPLIED MATERIALS & INTERFACES
(2022)
Article
Gastroenterology & Hepatology
Samuel Chuah, Joycelyn Lee, Yuan Song, Hyung-Don Kim, Martin Wasser, Neslihan A. Kaya, Kyunghye Bang, Yong Joon Lee, Seung Hyuck Jeon, Sheena Suthen, Shamirah A'Azman, Gerald Gien, Chun Jye Lim, Camillus Chua, Sharifah Nur Hazirah, Hong Kai Lee, Jia Qi Lim, Tony K. H. Lim, Joe Yeong, Jinmiao Chen, Eui-Cheol Shin, Salvatore Albani, Weiwei Zhai, Changhoon Yoo, Haiyan Liu, Su Pin Choo, David Tai, Valerie Chew
Summary: This study identifies immune cell subsets associated with response and irAEs in HCC patients receiving anti-PD-1 therapy and proposes a new combination immunotherapy for enhanced response without exacerbating adverse events.
JOURNAL OF HEPATOLOGY
(2022)
Article
Oncology
Zuzana Macek Jilkova, Arnaud Seigneurin, Celine Coppard, Laurissa Ouaguia, Caroline Aspord, Patrice N. Marche, Vincent Leroy, Thomas Decaens
Review
Biochemistry & Molecular Biology
Mariam Mroweh, Gael Roth, Thomas Decaens, Patrice N. Marche, Herve Lerat, Zuzana Macek Jilkova
Summary: Hepatocellular carcinoma (HCC) is a common cause of cancer-related deaths worldwide, with its incidence on the rise. Chronic inflammation plays a key role in hepatocarcinogenesis, and inhibition of Akt has effects on both cancer cells and the tumor microenvironment.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Gael S. Roth, Maxime Benhamou, Yann Teyssier, Arnaud Seigneurin, Melodie Abousalihac, Christian Sengel, Olivier Seror, Julien Ghelfi, Nathalie Ganne-Carrie, Lorraine Blaise, Olivier Sutter, Thomas Decaens, Jean-Charles Nault
Summary: Trans-arterial chemoembolization showed a significant increase in complete radiological response compared to bland embolization, but did not impact overall response or survival outcomes significantly. Both techniques had similar safety profiles in treating intermediate stage hepatocellular carcinoma.
Article
Oncology
Bleuenn Brusset, Jerome Dumortier, Daniel Cherqui, Georges-Philippe Pageaux, Emmanuel Boleslawski, Ludivine Chapron, Jean-Louis Quesada, Sylvie Radenne, Didier Samuel, Francis Navarro, Sebastien Dharancy, Thomas Decaens
Summary: The study compared the agreement for the criteria and outcomes of liver transplantation before and after the adoption of the AFP model, finding a longer waiting time and higher rate of bridging therapies after the AFP model was implemented, leading to poorer patient outcomes.
Review
Biochemistry & Molecular Biology
Lydie Carreres, Zuzana Macek Jilkova, Guillaume Vial, Patrice N. Marche, Thomas Decaens, Herve Lerat
Summary: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, and research is focusing on decoding the molecular mechanisms behind it to identify new therapeutic targets. Reliable, simple, and reproducible tools are necessary for investigating these pathways, with animal models such as diet-induced NAFLD and NASH being developed to mimic the human disease. Rat models, specifically the dietary model of NAFLD and NASH, are being used to study different dietary compositions and their effects on liver pathogenesis.
Article
Oncology
Nicolas Williet, Angelica Petrillo, Gael Roth, Michele Ghidini, Mila Petrova, Julien Forestier, Anthony Lopez, Audrey Thoor, Lucie Weislinger, Ferdinando De Vita, Julien Taieb, Jean Marc Phelip
Summary: Gemcitabine/nab-paclitaxel (GN) and FOLFIRINOX (FFX) were found to have no significant difference as first-line treatments in patients with locally advanced pancreatic cancer (LAPC) in terms of survival, tumor response, or tumor resection rate, according to a multicenter European study. Further trials are needed to confirm these findings.
Article
Oncology
Keerthi Kurma, Olivier Manches, Florent Chuffart, Nathalie Sturm, Khaldoun Gharzeddine, Jianhui Zhang, Marion Mercey-Ressejac, Sophie Rousseaux, Arnaud Millet, Herve Lerat, Patrice N. Marche, Zuzana Macek Jilkova, Thomas Decaens
Summary: Hepatocellular carcinoma (HCC) is the most common type of liver cancer, often associated with liver fibrosis or cirrhosis from chronic liver injuries. The liver's immune system plays a crucial role in disease progression towards HCC. The DEN-induced rat model of HCC exhibits molecular characteristics similar to human HCC, especially those with high proliferation, making it a valuable tool for preclinical testing.
Article
Cell Biology
Zuzana Macek Jilkova, Marie Noelle Hilleret, Theophile Gerster, Nathalie Sturm, Marion Mercey-Ressejac, Jean-Pierre Zarski, Vincent Leroy, Patrice N. Marche, Charlotte Costentin, Thomas Decaens
Summary: This study found that ICM, especially PD-1 and 4-1BB, are overexpressed in liver tissue from AIH patients, and there is a strong correlation between the abundance of PD-1(+) CD8(+) T-cells and the severity of AIH (alanine transaminase and aspartate transaminase levels). This suggests that ICM play a significant role in disrupting immune homeostasis in the liver, indicating their potential as targets for therapeutic interventions.
Article
Cell Biology
Lydie Carreres, Marion Mercey-Ressejac, Keerthi Kurma, Julien Ghelfi, Carole Fournier, Olivier Manches, Florent Chuffart, Sophie Rousseaux, Melanie Minoves, Thomas Decaens, Herve Lerat, Zuzana Macek Jilkova
Summary: This study investigated the impact of OSA-related chronic intermittent hypoxia on HCC progression using a HCC model. The study found that intermittent hypoxia further increased HCC cell proliferation, potentially contributing to an increased risk of HCC progression.
Article
Oncology
Gael S. Roth, Yohan Fayet, Sakina Benmameche-Medjahed, Francoise Ducimetiere, Amandine Charreton, Claire Cropet, Sylvie Chabaud, Anne-Marie Marion-Audibert, Olivier Berthelet, Thomas Walter, Mustapha Adham, Mathieu Baconnier, David Tavan, Nicolas Williet, Pascal Artru, Floriane Huet-Penz, Isabelle Ray-Coquard, Fadila Farsi, Helene Labrosse, Christelle de la Fouchardiere
Summary: This study analyzed the impact of care pathways, delays, and socio-spatial determinants on the diagnosis, treatment, and prognosis of pancreatic cancer patients. It found that general practitioners play a crucial role in cancer care, and centralization of pancreatic surgery is important for optimizing patient care and outcomes.
Article
Biochemistry & Molecular Biology
Keerthi Kurma, Ayca Zeybek Kuyucu, Gael S. Roth, Nathalie Sturm, Marion Mercey-Ressejac, Giovanni Abbadessa, Yi Yu, Herve Lerat, Patrice N. Marche, Thomas Decaens, Zuzana Macek Jilkova
Summary: The study demonstrates that vevorisertib, an allosteric AKT inhibitor, effectively suppresses tumor progression and improves liver fibrosis in a hepatocellular carcinoma (HCC) rat model. The combination of vevorisertib with sorafenib shows significant reduction in tumor growth compared to the control group. These findings provide a rationale for clinical testing of vevorisertib and highlight the importance of targeting AKT in HCC.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Immunology
Laurissa Ouaguia, Vincent Leroy, Tania Dufeu-Duchesne, David Durantel, Thomas Decaens, Margaux Hubert, Jenny Valladeau-Guilemond, Nathalie Bendriss-Vermare, Laurence Chaperot, Caroline Aspord
FRONTIERS IN IMMUNOLOGY
(2019)
Article
Oncology
Diego de Miguel-Perez, Edward M. Pickering, Umberto Malapelle, William Grier, Francesco Pepe, Pasquale Pisapia, Gianluca Russo, Joseph A. Pinto, Alessandro Russo, Giancarlo Troncone, Melissa J. Culligan, Katherine A. Scilla, Ranee Mehra, Pranshu Mohindra, Oscar Arrieta, Andres F. Cardona, Marzia Del Re, Ashutosh Sachdeva, Fred R. Hirsch, Andrea Wolf, Joseph S. Friedberg, Christian Rolfo
Summary: In this study, genetic alterations in resectable pleural mesothelioma tissues and blood samples were analyzed, and it was found that high tissue tumor mutational burden, tissue median minor allele frequency, blood tumor mutational burden, and specific mutations were correlated with outcomes in patients with resected PM. These findings suggest that molecular profiling could help identify longer survivors in patients with resected PM.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Davide Melisi, Camilla Zecchetto, Valeria Merz, Giuseppe Malleo, Luca Landoni, Alberto Quinzii, Simona Casalino, Federica Fazzini, Marina Gaule, Camilla Pesoni, Luca Casetti, Alessandro Esposito, Giovanni Marchegiani, Cristiana Piazzola, Mirko D'Onofrio, Riccardo de Robertis, Armando Gabbrielli, Laura Bernardoni, Stefano F. Crino, Silvia Pietrobono, Claudio Luchini, Camillo Aliberti, Guido Martignoni, Stefano Milleri, Giovanni Butturini, Aldo Scarpa, Roberto Salvia, Claudio Bassi
Summary: This study evaluated the safety and activity of liposomal irinotecan in the perioperative treatment of resectable pancreatic ductal adenocarcinoma (rPDAC) patients. The results showed that NALIRIFOX has manageable and active outcomes, and should be further investigated in randomized trials comparing it to standard upfront surgery followed by adjuvant therapy.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Eric Jonasch, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. Mcdermott, M. Dror Michaelson, Leonard J. Appleman, Ananya Roy, Rodolfo F. Perini, Yanfang Liu, Toni K. Choueiri
Summary: After a median follow-up of 41.2 months, belzutifan monotherapy demonstrated durable antitumor activity in patients with advanced ccRCC and acceptable safety.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Patricia A. H. Hamers, Geraldine R. Vink, Marloes A. G. Elferink, Leon M. G. Moons, Cornelis J. A. Punt, Anne M. May, Miriam Koopman
Summary: Screen-detection of the primary tumor is associated with longer overall survival after metachronous metastasis.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Camilla Nero, Nicolo Bizzarri, Stefano Di Berardino, Francesca Sillano, Giuseppe Vizzielli, Francesco Cosentino, Virginia Vargiu, Pierandrea De Iaco, Anna Myriam Perrone, Enrico Vizza, Benito Chiofalo, Stefano Uccella, Fabio Ghezzi, Luigi Carlo Turco, Giacomo Corrado, Diana Giannarelli, Tina Pasciuto, Gian Franco Zannoni, Anna Fagotti, Giovanni Scambia
Summary: This study evaluates the sensitivity and specificity of sentinel-lymph-node mapping compared to systematic lymphadenectomy in detecting lymph node metastasis in early stage ovarian cancer. The results show that sentinel-lymph-node mapping did not reach the expected sensitivity, but ultra-staging protocol improved the accuracy of diagnosis for patients.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies
Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Savannah Roy, Stephanie Lakritz, Anna R. Schreiber, Elizabeth Molina Kuna, Cathy J. Bradley, Lavanya Kondapalli, Jennifer R. Diamond
Summary: This study evaluates major adverse cardiovascular events (MACE) in older women with TNBC treated with anthracycline and taxane-based chemotherapy (ATAX) compared to taxane-based chemotherapy (TAX). The results show that ATAX does not increase the risk of MACE and there is no difference in survival between patients who received TAX and ATAX.
EUROPEAN JOURNAL OF CANCER
(2024)
Letter
Oncology
Pei-Chun Weng, Yau-Li Huang, Chun-Yu Cheng
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank
Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Casper W. F. van Eijck, Gaby Strijk, Eveline E. Vietscha, Fleur van der Sijde, Maaike Verheij, Dana A. M. Mustafa, Madelief Vinkc, Joachim G. J. V. Aerts, Casper H. J. van Eijck, Marcella Willemsen
Summary: The study reveals that FOLFIRINOX has immunomodulatory effects, suggesting its potential in immune-based combination therapies for pancreatic cancer. Additionally, certain plasma proteins hold promise as circulating predictive biomarkers for early prediction of FOLFIRINOX response in patients with pancreatic cancer.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Marwan Fakih, Chongkai Wang, Jaideep Sandhu, Jian Ye, Colt Egelston, Xiaochen Li
Summary: This study explores the impact of metastatic sites on treatment outcomes for chemotherapy-refractory colorectal cancer patients. It found that patients with liver or peritoneal metastases had poor treatment outcomes, while those with lung-only metastases showed significant response. The presence of concurrent lymph node or other extrahepatic metastatic disease diminished treatment response in patients with lung metastases. Future checkpoint inhibitor trials should stratify patients based on metastatic locations.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Georgios Christos Tsiatsianis, Candace S. Y. Chan, Ioannis Mouratidis, Nikol Chantzi, Anna Maria Tsiatsiani, Nelson S. Yee, Apostolos Zaravinos, Verena Kantere, Ilias Georgakopoulos-Soares
Summary: The study reveals that nullpeptides can serve as biomarkers for cancer detection and treatment, particularly in highly recurrent cancer patients. These nullpeptides primarily occur in highly expressed genes, particularly in specific loci of oncogenes and tumor suppressors. Recurrent nullpeptides are more likely to be found in neoantigens, which play a significant role in immunotherapy.
EUROPEAN JOURNAL OF CANCER
(2024)